Doravirine
Clinical data
Trade namesPifeltro
Other namesMK-1439
AHFS/Drugs.comMonograph
MedlinePlusa618048
License data
Routes of
administration		By mouth[1][2]
ATC code
Legal status
Legal status
Identifiers
  • 3-Chloro-5-({1-[(4-methyl-5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)-1,2-dihydro-3-pyridinyl}oxy)benzonitrile
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard100.234.454 Edit this at Wikidata
Chemical and physical data
FormulaC17H11ClF3N5O3
Molar mass425.75 g·mol−1
3D model (JSmol)
  • Cn1c(n[nH]c1=O)Cn2ccc(c(c2=O)Oc3cc(cc(c3)Cl)C#N)C(F)(F)F
  • InChI=1S/C17H11ClF3N5O3/c1-25-13(23-24-16(25)28)8-26-3-2-12(17(19,20)21)14(15(26)27)29-11-5-9(7-22)4-10(18)6-11/h2-6H,8H2,1H3,(H,24,28)
  • Key:ZIAOVIPSKUPPQW-UHFFFAOYSA-N

Doravirine, sold under the brand name Pifeltro, is a non-nucleoside reverse transcriptase inhibitor medication developed by Merck & Co. for use in the treatment of HIV/AIDS.

Doravirine was approved for medical use in the United States in August 2018.[7]

References

  1. ^ a b "Pifeltro- doravirine tablet, film coated". DailyMed. 10 October 2019. Retrieved 22 September 2020.
  2. ^ Collins S, Horn T. "The Antiretroviral Pipeline" (PDF). Pipeline Report. p. 10. Archived from the original (PDF) on 11 March 2016. Retrieved 6 December 2015.
  3. ^ "PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION : PIFELTRO" (PDF). Pdf.hres.ca. Retrieved 5 June 2022.
  4. ^ "Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Retrieved 17 April 2024.
  5. ^ "Pifeltro 100 mg film-coated tablets - Summary of Product Characteristics (SmPC)". Medicines.org.uk. Retrieved 1 October 2020.
  6. ^ "Pifeltro EPAR". European Medicines Agency (EMA). Retrieved 1 October 2020.
  7. ^ "Drug Approval Package: Pifeltro (doravirine)". U.S. Food and Drug Administration (FDA). 9 October 2018. Retrieved 22 September 2020.


Categories